United Therapeutics Corporation $UTHR Stake Lowered by Morningstar Investment Management LLC

Morningstar Investment Management LLC cut its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 54.9% during the first quarter, HoldingsChannel reports. The fund owned 1,573 shares of the biotechnology company’s stock after selling 1,912 shares during the quarter. Morningstar Investment Management LLC’s holdings in United Therapeutics were worth $933,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of UTHR. Torren Management LLC purchased a new position in United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management increased its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics during the 4th quarter valued at about $31,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. HC Wainwright boosted their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Bank of America reduced their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Raymond James Financial began coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Royal Bank Of Canada increased their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $648.33.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $552.56, for a total transaction of $4,586,248.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,960,240.32. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $535.99, for a total value of $5,091,905.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $21,714,562.87. This trade represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 513,333 shares of company stock worth $286,933,042. 8.60% of the stock is currently owned by insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $528.47 on Friday. The stock has a market capitalization of $22.43 billion, a P/E ratio of 19.51, a P/E/G ratio of 1.77 and a beta of 0.58. The business has a 50-day moving average of $547.88 and a two-hundred day moving average of $531.39. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the company posted $6.63 EPS. The business’s revenue was down 1.6% on a year-over-year basis. As a group, research analysts expect that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.